AnergiX: Phase I/II

Final results from CRXA's 31-patient Phase I/II trial showed that AnergiX.RA was safe and well tolerated at intravenous

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE